This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moving Average Crossover Alert: Flex (FLEX)
by Zacks Equity Research
Flex Ltd. (FLEX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Flex (FLEX) Q4 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Flex's (FLEX) fourth-quarter fiscal 2018 results benefits from new business wins driven by the Sketch-to-Scale initiative.
Flex (FLEX) to Divest Interests in Multek Operation to MFLEX
by Zacks Equity Research
Flex (FLEX) signed a definite agreement to divest its US-based Multek operation to Multi-Fineline Electronix Inc.
Why Is Flex Ltd. (FLEX) Down 4.5% Since its Last Earnings Report?
by Zacks Equity Research
Flex Ltd. (FLEX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Flex (FLEX) Q3 Earnings Beat, Revenues Grow on Deal Wins
by Zacks Equity Research
Flex's (FLEX) third-quarter fiscal 2018 results benefit from new business wins driven by the Sketch-to-Scale initiative.
Why Should You Retain Flex (FLEX) Stock in Your Portfolio
by Zacks Equity Research
Flex (FLEX) seems to be one such stock, which investors need to retain if they are looking to reap long-term benefits.
Why Is Flex (FLEX) Up 10% Since the Last Earnings Report?
by Zacks Equity Research
Flex (FLEX) reported earnings about 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Consider Flex Ltd. (FLEX) Stock?
by Zacks Equity Research
Flex Ltd. (FLEX) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
Flex Q2 Earnings & Revenues Beat Estimates, View Impressive
by Zacks Equity Research
Flex fiscal second-quarter 2018 results were driven by double-digit growth in its IEI and HRS segments. However, higher investments kept margins under pressure.
Plexus (PLXS) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Plexus' (PLXS) fiscal fourth-quarter 2017 adjusted earnings of 84 cents per share beat the Zacks Consensus Estimate but revenues of $670 million fell way short of the consensus mark of $681 million.
Why Earnings Season Could Be Great for Flextronics (FLEX)?
by Soumic Nandy
Flextronics (FLEX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings
New Strong Sell Stocks for August 22nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Flex (FLEX) Misses on Q1 Earnings, Beats Revenue Estimates
by Zacks Equity Research
Flex Ltd. (FLEX) missed first-quarter earnings estimates on higher operating expenses due to the Nike partnership
Plexus (PLXS) Q3 Earnings, Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Shares of Plexus Corp (PLXS) were up 6.1% after reporting better-than-expected third-quarter fiscal 2017 results.
New Strong Sell Stocks for May 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
What Falling Estimates & Price Mean for Flex Ltd. (FLEX)
by Zacks Equity Research
A stock that you may want to consider dropping is Flex Ltd. (FLEX), which has witnessed a significant price decline in the past four weeks
Plexus (PLXS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Plexus Corp (PLXS) reported second-quarter fiscal 2017 adjusted earnings of 84 cents per share, which beat the Zacks Consensus Estimate of 76 cents and grew 52.7% year over year.
Plexus (PLXS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Plexus Corp (PLXS) reported first-quarter fiscal 2017 adjusted earnings of 82 cents per share, which beat the Zacks Consensus Estimate but revenues of $635 million missed the same.
Why the P/S Ratio is My Favorite Valuation Metric
by Kevin Matras
This week, Kevin Matras shows how to use the Price to Sales ratio. Highlighted stocks include FLEX, CDW, TLYS, CTRN and CAH.